STOCKS TELEGRAPH

Tag: CELC

  • 3 Stocks Poised for a Breakout: Idexx Laboratories (IDXX), Celcuity (CELC), Cardiol Therapeutics (CRDL)

    3 Stocks Poised for a Breakout: Idexx Laboratories (IDXX), Celcuity (CELC), Cardiol Therapeutics (CRDL)

    The search for differentiated opportunities is leading investors deeper into niche segments of the biotech landscape. Businesses targeting underserved indications or leveraging novel platforms are beginning to stand out, especially when early data suggests the potential to disrupt existing standards of care.

    Idexx Laboratories Inc (IDXX)

    Idexx Laboratories Inc (NASDAQ: IDXX) opened the trading on April 17, 2026, with great promise as it jumped 3.39% to $589.25. During the day, the stock rose to $594.52 and sunk to $577.37. Taking a more long-term approach, IDXX posted a 52-week range of $402.85-$769.98.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 14.28%. Meanwhile, its Annual Earning per share during the time was 14.28%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 10.93%. This publicly-traded company’s shares outstanding now amounts to $79.71 million, simultaneously with a float of $78.54 million. The organization now has a market capitalization sitting at $46.80 billion.

    Celcuity Inc (CELC)

    Celcuity Inc (NASDAQ: CELC) started the day on April 17, 2026, with a price decrease of -2.23% at $122.46. During the day, the stock rose to $125.66 and sunk to $121.46. Taking a more long-term approach, CELC posted a 52-week range of $9.50-$127.34.

    It was noted that the giant of the Healthcare sector posted annual sales growth of -32.62% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -32.62%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is -3.25%. This publicly-traded company’s shares outstanding now amounts to $48.24 million, simultaneously with a float of $37.81 million. The organization now has a market capitalization sitting at $5.92 billion.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is expanding its long-term growth strategy by advancing a diversified pipeline that targets both niche and large-scale cardiovascular markets. This approach enables the company to balance near-term opportunities with broader, high-value indications such as heart failure.

    Market Momentum

    As of April 17, 2026, CRDL closed at $1.51, up 7.09%, with trading volume (1.34M shares) more than double its average of 596,993 shares—highlighting strong investor interest and momentum. With a market cap of $168.637M, the stock is approaching the upper end of its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.44 continues to suggest meaningful upside potential as pipeline programs advance.

    Pipeline Expansion: CRD-38

    The company is developing CRD-38, a next-generation, subcutaneously administered therapy designed for more convenient dosing and broader use, particularly in heart failure. This asset targets both inflammation and fibrosis, two key drivers of disease progression that remain largely unaddressed by current treatments.

    Market Opportunity

    Heart failure represents a multi-billion-dollar global market with millions of patients and limited therapies targeting inflammatory pathways. By advancing CRD-38, Cardiol is positioning itself to enter this large and underserved space, significantly expanding its potential addressable market beyond pericarditis and myocarditis.

    Outlook

    As CRD-38 progresses toward clinical development, it could serve as a major growth engine for the company. Success in this program would meaningfully enhance Cardiol’s long-term value proposition and market positioning.

  • Celcuity Inc. (CELC) stock soared in the after-market trading session; here’s what recently happened

    Celcuity Inc. (CELC) stock soared in the after-market trading session; here’s what recently happened

    Celcuity Inc. (CELC) shares went up by 4.87% to trade at $29.3 in after-market at the time of writing. CELC stock closed Monday’s session at $27.94 which is a 29.35% gain. The CELC stock volume traded around 4.86 million shares, which was higher than the average daily volume of 0.46 million shares within the past 50 days

    What is the recent news on Cecluity’s operational activities?

    On 12th April, Celcuity participated in the American Association for Cancer Research (AACR) Annual Meeting and there presented the outcomes of its studies which evaluated gedatolisib, inavolisib, and navitoclax in breast and ovarian patient tumors. Gedatolisib is a pan-P13K/mTOR inhibitor, inavolisib is a P13K-α inhibitor and navitoclax is a BCL inhibitor. Two e-posters were used by the company for the presentation of these studies and result.

    Results and characteristics of the study

    The posters presented the use of CELsignia test to characterize the role of RAS network nodes; CELsignia RAS Network Activity test that is used by the company identifies hyperactive RAS network signal done by the ovarian or breast cancer patients’ tumors. Furthermore, CELsignia also characterizes gedatolisib, inavolisib, navitoclax as well as RAS signaling role in the phospholipid-initiated signaling activity that is done through the lysophosphatidic acid (LPA) receptor family of GPCRs in the tumor cells and cell lines of ovarian and breast cancer patients.

    The results of these studies indicated that there is a potential advantage of not just inhibiting P13k-α signaling but inhibiting all Class 1 P13K isoforms as well as mTOR for treating P13K signaling tumors.

    Licensing agreement with pharma-giant Pfizer

    The CELC stock soared more than 50% on 9th April after it announced a licensing agreement with the world-renowned pharma-company Pfizer PFE. In the agreement, Celcuity paid $10 million to Pfizer in upfront payment as per the terms and Pfizer will receive up to $330 million in development and sales-based milestone from Celcuity along with royalties on future sales.

    Furthermore, Celcuity also announced a promise to present the preliminary data on the recent ongoing phase 1b  study evaluating gedatolisib in combination with Pfizer’s Ibrance as well as an endocrine therapy in Er+/HER2 – advanced or metastatic breast cancer patients. Phase II/III study of gedatolisib with the pfixer combo is expected to start in mid of 2022.

    Insight on Celcuity’s overall background

    Celcuity is a clinical stage biotechnology company that is specifically creating novel therapies and treatments in a unique and innovative approach towards cancer treatments. The company is differentiated based on its focus on creating integrated companion diagnostics and therapeutic strategy for cancer patients. The objective of this focus is to enhance and extend the lives of cancer patients.

    The companion diagnostics is able to identify the cancer driver in the patient and then the therapeutic efforts target the cancer driver molecularly. The proprietary diagnostic platform of CELC stock is known as CELsignia which has the tech-ability to analyze the live tumor cells that then identify new groups of cancer patients for whom targeted therapies are favorable. This diagnosis is furthered by CELsigniaCDx that supports the advancement new developing indications for the established targeted therapies.

    Based on this therapeutic strategy and integrated companion diagnostic, Celcuity is positioned in the cancer treatment and therapy market uniquely to treat the cancer driver in the most suited way possible for the patients.